Biosimilars

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Despite the establishment of a specific approval pathway, the issuance of detailed scientific guidelines for the development of… (More)
Is this relevant?
2014
2014
Biosimilars have the potential to lead to enormous cost savings in healthcare without reducing the level of care for patients. In… (More)
  • table 1
  • table 2
Is this relevant?
Review
2012
Review
2012
Biosimilar medicinal products (biosimilars) have become a reality in the European Union and will soon be available in the United… (More)
Is this relevant?
Review
2012
Review
2012
Biologics such as monoclonal antibodies are much more complex than small-molecule drugs, which raises challenging questions for… (More)
  • figure 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
The development of biologic therapeutics using advanced technology to copy and improve on nature's design of complex peptides… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
volume 30 number 12 DeCember 2012 nature biotechnology program, such as pregnant women, pediatric or elderly patients, or… (More)
  • table 1
Is this relevant?
2012
2012
The development of biological products is associated with high costs [2, 3]. This, together with the increase in the use of… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
n engl j med 365;5 nejm.org august 4, 2011 385 ditions (see graph). Therapeutic biologics such as genetically engineered… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Patents for the first generation of approved biopharmaceuticals have either expired or are about to expire. Thus the market is… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?